Cipla USA, Inc. is recalling 54,583 units of Lanreotide Injection (120 mg/0.5 mL) because a contract manufacturing site failed to follow proper visual inspection procedures, leading to a lack of assurance that the product is sterile. This recall involves pre-filled syringes sold at pharmacies nationwide. While no incidents or injuries have been reported to date, the lack of sterility in an injectable medication poses a significant health risk.
If an injectable drug is not sterile, it can introduce bacteria or other contaminants directly into the bloodstream or tissues, potentially causing serious infections or life-threatening systemic illness.
You have 2 options:
Manufactured by Pharmathen International, S.A., Rodopi, Greece.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.